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mial pneumonia (NP) is associated with higher resource utilization, increased hospital stays,
and mortality. We present a health economics model to understand the impact of using line-
zolid as the first-line treatment of MRSA NP in Taiwan.
Methods: We developed a cost-effectiveness model to estimate the costs and clinical out-
comes of using linezolid 600 mg b.i.d. versus vancomycin 15 mg/kg b.i.d. as the first-line treat-
ment of MRSA NP in Taiwan. The model is a decision-analytic analysis in which a MRSA-
confirmed patient is simulated to utilize one of the treatments, using data from a clinical trial.
Within each treatment arm, the patient can or cannot achieve clinical cure. Regardless of
whether the clinical cure was achieved or not, the patient may or may not have experienced
an adverse event. The per-protocol results for clinical cure were 57.6% and 46.6% for linezolid
and vancomycin, respectively.ediatric Infection Disease, Department of Pediatrics, Chang Gung Memorial Hospital, 5,
333, Taiwan.
h.org.tw (Y.-C. Huang).
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Cost-effectiveness of Linezolid in MRSA NP 47Results: The total cost of linezolid was $376 more per patient than that of vancomycin. Drug
costs were higher for linezolid than for vancomycin ($1108 vs. $233), and hospitalization costs
were lower ($4998 vs. $5496). With higher cost and higher cure rates for linezolid, the incre-
mental cost per cure was $3421.
Conclusion: This study projects linezolid to have higher drug costs, lower hospital costs, and
higher overall costs compared with vancomycin. This is balanced against the higher clinical
cure rate for linezolid. Depending on the willingness to pay for clinical cure, linezolid could
be cost effective as the first-line treatment of NP in Taiwan.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Hospital-acquired pneumonia or nosocomial pneumonia
(NP) is characterized by the pneumonia that a patient ac-
quires 2 days or 3 days after being admitted to the hospital.
Methicillin-resistant Staphylococcus aureus (MRSA) is
responsible for many cases of NP in Taiwan.1 This disease is
associated with higher resource utilization, increased hos-
pital stays, and mortality.2 A recent study in Taiwan sug-
gests an excess 1-year mortality of 20.2% for patients with
S. aureus health care-associated infections, as well as
increased ventilator dependence and dialysis.3
Vancomycin, a glycopeptide antibiotic, has been the
standard of care since the 1980s for treating NP in Taiwan.
Typical treatment regimens include using vancomycin from
empiric treatment through confirmation, but recent find-
ings suggest that doing so may be suboptimal.4 Not only is
vancomycin associated with nephrotoxicity, but there have
also been reports that vancomycin-nonsusceptible organ-
isms are becoming more common.5 Teicoplanin, a semi-
synthetic glycopeptide antibiotic, has also been used in a
manner similar to vancomycin. Recently, linezolid, the first
member of the oxazolidine class of drugs, has been rec-
ommended as one of the antibiotics of choice for treatment
of MRSA pneumonia, both in the United States and in
Taiwan.6
In this study, we present a health economics and out-
comes research (HEOR) model to understand the impact of
using linezolid as the first-line treatment of MRSA NP in
Taiwan. HEOR provides a model framework to understand
the tradeoffs between competing optionsdin this case,
vancomycin versus linezolid. The tradeoffs include costs
(e.g., hospital utilization, pharmacy costs, and laboratory
tests) and outcomes (clinical cure) associated with treat-
ment choices. HEOR models include cost-effectiveness
studies, which estimate the value for money of new
treatments on a per-patient basis using common units, such
as clinical cure, progression-free survival, and life years.
The output expresses the incremental cost-effectiveness
ratio (ICER) of the competing treatments.
Health technology assessment (HTA) committees often
consult HEOR studies in their evaluations. The ICERs from
cost-effectiveness analyses can be used by HTA bodies to
support inclusion or exclusion recommendations of new
treatments in health systems. For example, HTAs may have
ICER thresholds above which treatments are not consideredto be cost effective and thus are not recommended for
reimbursement. Some HTAs utilizing this type of analysis
include the National Institute for Health and Clinical
Excellence in the United Kingdom, Blue Cross Blue Shield’s
Technology Assessment Committee in the United States,
and the Center for Disease Evaluation in Taiwan.7 To eval-
uate new technologies, the Center for Disease Evaluation
conducts systematic reviews of reports from other HTA
agencies, but they also recommend studies based on local,
Taiwanese data. The model presented in this study is a
localized HEOR model for the treatment of MRSA NP in
Taiwan.Methods
Model overview
We developed a cost-effectiveness model in Microsoft Excel
(Microsoft Inc., Redmond, WA, USA) to estimate the costs
and clinical outcomes of using linezolid 600 mg b.i.d. versus
vancomycin 15 mg/kg b.i.d. as the first-line treatment of
NP in Taiwan. We based the analysis on the results of the
ZEPHyR (Linezolid in the treatment of subjects with noso-
comial pneumonia proven to be due to methicillin-resistant
Staphylococcus aureus) clinical trial, a randomized, double-
blind, multicenter study. Note that the trial was global,
with patients being enrolled at various sites in the United
States, Europe, Asia, South America, and other regions. For
additional details on the patient demographics, we refer
readers to the original trial publication.8 The assessment
was conducted from a payer’s perspective, and the time-
frame is the same duration of the end of study in the trial,
7e30 days after end of treatment.
The final output is the incremental cost per cure (ICPC),
which measures the additional monetary cost of achieving a
clinical cure in an additional patient.
The model is a decision-analytic model the structure of
which mimics that of the ZEPHyR clinical trial design
(Figure 1). An MRSA-confirmed patient is simulated to uti-
lize one of the following treatments: linezolid 600 mg b.i.d.
or vancomycin 15 mg/kg b.i.d. Within each treatment arm,
the patient can or cannot achieve clinical cure; in line with
the trial protocol, clinical cure was defined as the resolu-
tion of clinical signs and symptoms of pneumonia,
improvement or lack of progression in chest imaging, and
Figure 1. Decision-analytic framework. Rates of clinical cure and adverse events for linezolid and vancomycin were derived from
ZyPHER study. MRSA Z methicillin-resistant Staphylococcus aureus.
48 P.-C. Lin et al.no requirement for additional antibacterial treatment at
the end of the study. Regardless of whether the clinical
cure was achieved or not, the patient may or may not have
experienced an adverse event. The “adverse event” arm in
Figure 1 includes events considered clinically important in
the intent-to-treat population: anemia, renal failure/
impairment/azotemia, cardiac arrest, thrombocytopenia,
pancreatitis, polyneuropathy, pancytopenia/neutropenia,
and paresthesia. The probability of each event is described
in the following section.
Probabilities
Probabilities of clinical events were obtained directly from
the clinical trial. Clinical cure rates were based on the
primary endpoint, per-protocol results at the end of the
study: 57.6% for linezolid and 46.6% for vancomycin. Prob-
abilities of the adverse events are shown in Table 1. The
aggregate adverse event rates for linezolid and vancomycin
are 13.40% and 19.76%, respectively, which are the sum-
mation of the individual rates.
Costs
We used a microcosting approach by estimating the product
of the utilization quantities and the unit costs. Based on an
average of 10 days of treatment per patient in the ZEPHyR
clinical trial, the total number of hospital and intensiveTable 1 Probabilities of clinical cure and adverse events by lin
Input Linezolid (%) Vanco
Efficacy (clinical success rate) 57.60 46.60
Adverse event rates
Anemia 5.03 7.16
Renal failure/impairment/azotemia 3.69 7.33
Cardiac arrest 1.84 2.21
Thrombocytopenia 1.34 2.21
Pancreatitis 0.84 0.17
Polyneuropathy 0.00 0.17
Pancytopenia/neutropenia 0.67 0.34
Paresthesia 0.00 0.17
AE Z adverse event; EOS Z end of study; PP Z per protocol.care unit (ICU) days were 17.2 days and 10.1 days for
linezolid and 18.1 days and 10.6 days for vancomycin,
respectively. While in the hospital, vancomycin-treated
patients were tested daily for serum creatinine levels,
serum vancomycin levels, and complete blood counts.
Linezolid-treated patients were monitored for serum
creatinine levels and complete blood counts. For both
treatments, the number of physician visits per day during
the inpatient stay was assumed to be one. If the patient
experiences an adverse event, it results in additional 1.7
days in the general ward. Treatment failure led to addi-
tional 2 days in the general ward.9e11
Medication costs were derived from the National Health
Insurance database, and were $55.40 and $11.67 for line-
zolid intravenous (IV) 600 mg and vancomycin 1 g, PDS
(polydioxanone) IV, respectively. Treatment and utilization
costs were estimated from public sources (Table 2). In our
analysis, the increased costs associated with adverse
events were assumed to be limited to costs incurred from
the resulting additional length of hospital stay.Sensitivity analysis
To examine the robustness of our results, sensitivity anal-
ysis was performed. We varied the clinical probabilities and
costs by 5%, 10%, and 20%, and performed one-way sensi-
tivity analysis. In the one-way sensitivity analysis, we
changed a single parameter and calculated the resultingezolid and vancomycin, respectively.
mycin (%) Source
Clinical response ratedPP at EOS data
Clinically important investigator-reported
all-cause AEs in the intent-to-treat population
Table 2 Unit costs for inpatient costs and associated laboratory works.
Input Unit cost ($)a Source
Inpatient cost/d (general ward) 76.85 Sheng et al (2005)24 estimated inpatient costs,
including accommodation & material/service costs
Inpatient cost/d (ICU) 419.6 Sheng et al (2005)24 estimated inpatient costs,
including accommodation & material/service costs
Lab work (serum creatinine levels) 1.33 NHIA website
Lab work (serum vancomycin levels) 10.67 NHIA website
Lab work (complete blood count) 6.67 NHIA website
a Costs were estimated in local currency of Taiwan and their values were converted to USD using the formula 1 USD Z 30 TWD.
ICU Z intensive care unit; NHIA Z National Health Insurance Administration; TWD Z Taiwan dollar; USD Z US dollar.
Cost-effectiveness of Linezolid in MRSA NP 49ICPC based on the high and low estimates of that
parameter.Results
In the ZEPHyR study, characteristics of the patient pop-
ulations between the linezolid and vancomycin arms were
generally balanced with disproportionately more males and
whites. In this base case, the total cost of linezolid was
$376 more per patient than that of vancomycin (Table 3).
Drug costs were found to be higher for linezolid than for
vancomycin ($1108 vs. $233), and hospitalization costs
were lower ($4998 vs. $5496). The per-protocol results for
clinical cure at the end of the study were 57.6% and 46.6%
for linezolid and vancomycin, respectively, statistically
different at p Z 0.042. With higher cost and higher cure
rates for linezolid, the ICPC was $3421. With a conservative
assumption of 14 days of treatment duration per patient,
the ICPC was moderately increased to $6601.
The nondrug costs for linezolid were as follows: ICU
$4238, ward (clinical cure) $546, ward (no clinical cure)
$699, laboratory (clinical cure) $138, and laboratory (no
clinical cure) $154. Costs for vancomycin were as follows:
ICU $4448, ward (clinical cure) $576, ward (no clinical cure)
$730, laboratory (clinical cure) $172, and laboratory (no
clinical cure) $191. ICU charges accounted for the largest
nondrug cost between the treatments, with vancomycin
costing $210 more than linezolid.
Sensitivity analysis results
By varying the parameters by  5% individually, the ICPC
ranges from $1714 to $5127, a spread of $3413 (Figure 2).
Clinical parameters had the largest impact on ICPC, led byTable 3 Base case results of incremental costs-effectiveness ra
Drug Costs (USD)
Drug costs ($) Hospitalization costs ($) To
Vancomycin 233 5496 57
Linezolid 1108 4998 61
Incremental 875 498 3
USD Z US dollar.the number of days in ICU and clinical cure rate: an in-
crease in vancomycin ICU days decreases the ICPC and
results in linezolid appearing relatively more cost effec-
tive. Cost components (i.e., drug costs, dosage, and
treatment duration) did not influence ICPC as much as the
clinical parameters. Variation in the cost of linezolid
600 mg from $52.63 to $58.17 changed the ICPC from
$2917 to $3924. Similar hierarchies of parameter influence
were observed by varying the parameters in the range of
10e20%.
Discussion
To our knowledge, this is the first study to evaluate the
cost effectiveness of treating MRSA NP with linezolid
versus vancomycin in Taiwan. The decision-analytic model
was based on the ZEPHyR clinical trial, using clinical cure
as the outcome. The results suggest linezolid to have
higher drug costs, lower hospital costs, and higher overall
costs compared with vancomycin. This is balanced against
the higher clinical cure rate for linezolid, resulting in an
ICPC of $3421. The finding that linezolid has higher costs
and better outcomes is consistent with the previously
published literature. Mullins et al12 performed a claims
database analysis in the USA and estimated $3600 as the
incremental cost per life saved for linezolid. In addition,
for the USA, Shorr et al13 estimated the cost per quality-
adjusted life year (QALY) of linezolid versus vancomycin
to be approximately $30,000 and concluded it as a cost-
effective treatment option. For Spain, Grau et al14 and
Leo´n et al15 calculated ratios of V349 per QALY and V406
per life year gained, respectively. In Germany, Gru¨newald
et al16 constructed a decision analytic model based on the
published sources and physician interviews, and their
analysis suggests a ratio of V7756 per additional patienttio.
Effectiveness Incremental cost per
cured person ($)tal costs ($) % of patients cured
29 47 d
06 58 d
76 11 3421
Figure 2. One-way sensitivity analysis by changing a single clinical parameter or cost. ICU Z intensive care unit;
IV Z intravenous.
50 P.-C. Lin et al.cured. In Argentina, Aiello et al17 estimated the incre-
mental cost per life year gained to be $482. In an analysis
for France, De Cock et al18 found linezolid to be cost
saving as well as to have better clinical outcomes relative
to vancomycin.
In our analysis, we used clinical cure as the effective-
ness measure, because it was the primary endpoint of the
ZEPHyR trial and the timeframe of the model was short, so
life year measures would be difficult to forecast. This
approach is consistent with that reported in papers in this
disease area and others.14 Using a disease-specific
outcome measure, it is difficult to conclude whether or
not the results are cost effective; to our knowledge, no
research has been conducted regarding the willingness to
pay of clinical cures for NP. World Health Organization
guidelines suggest two to three times gross domestic
product per capita as the appropriate threshold for
considering a treatment to be cost effective.19 In Taiwan,
this range would be $42e63K20 per life year saved. If we
consider the lack of clinical cure to result in death within 1
year of the end of the clinical trial, our results would
indicate linezolid to be cost effective because our ICPC is
$3421, which is below the threshold range in Taiwan.
However, without a translation to a common denominator
such as a QALY, it would be difficult for payers to make
coverage decisions across disease areas.
The short-duration timeframe stems from the choice of
using the clinical trial protocol as the structure of the
model. Like most economic models, this analysis is
intended to be a parable of the disease area, and we
balance the tradeoff between tractability and realism.
This approach is in line with other studies in the field of
health economics, which use clinical trial data in the
model.21,22 The alternative of using real-world data is also
not without difficulties: each health system, hospital, and
doctor may have a different way of treating the patient.
Although the trial was conducted in multicenter, interna-
tional settings, we acknowledge that it may not fully
represent treatment patterns in Taiwan. For example,
patients may have a longer length of stay because hospi-
tals do not encourage discharge. Costs and utilization may
vary across hospitals and regions. Moreover, we assumed
that laboratory tests would be conducted in patients every
day, which might not be the case in practice. Thesensitivity analysis suggests that the utilization and cost of
laboratory work have very little impact on the final re-
sults. Despite these limitations, the sensitivity analysis
suggests that the results hold under different assumptions
and scenarios.
An extension to this model would be to increase the
timeframe of the model by making assumptions for out-
comes beyond the clinical trial. For example, NP may be
associated with higher costs in the long run, and some
researchers have suggested that hospital stays are corre-
lated with higher healthcare costs in the future.23 By
extending the model, QALY differences may be more
pronounced, which will allow the outcomes to be
expressed in cost/QALY terms in addition to ICPC. Some
shortcomings of the current framework include the
following: mortality rates in the two arms of the clinical
trial were not statistically different, so the rates did not
play a role in the analysis. If new data suggest different
mortality rates, it may be a key driver in determining the
cost effectiveness of linezolid. In addition, adverse events
and treatment failure are assumed to only affect the
length of stay in the hospital ward, which may be a
simplistic generalization. Besides, there might be some
overlap/double counting in hospital days due to adverse
events, since these events also contributed to the total
length of stay in the ZEPHyR study. Lastly, we leave it to
future researchers to compare our results with other
sources, such as prospective or retrospective datasets.
In summary, with better clinical response and less
nephrotoxicity in the ZEPHyR study, first-line treatment of
MRSA NP with linezolid was associated with higher drug
costs and lower hospital costs in Taiwan, compared to
vancomycin treatment. Depending on the cost-
effectiveness threshold, linezolid may be a cost-effective
treatment strategy for MRSA NP in Taiwan.Conflicts of interest
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